Ultra‐low‐molecular‐weight heparin vs placebo
Symptomatic DVT · ambulatory cancer patients receiving chemotherapy
Ultra‐low‐molecular‐weight heparin leads to lower symptomatic DVT compared with placebo (high certainty).
1 finding from 1 review
- Primary prophylaxis for venous thromboembolism in ambulatory cancer patients receiving chemotherapy 2020 · Cochrane Headline outcomes onlyRR 0.32 [0.16, 0.63]1 study · 3212 participantsHigh